Press release
The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180 billion by 2030, predicts Roots Analysis
Roots Analysis is pleased to announce the publication of its recent study, titled “Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030” report to its list of offerings.
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html
The report provides a detailed study on the current market landscape and future potential of biologics designed for subcutaneous administration. In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants) that enable subcutaneous delivery of the biologic drugs. Amongst other elements, the report features the following:
A detailed assessment of the current market landscape of commercially available and clinical-stage biologics that are designed for delivery via the subcutaneous route
A case study on leading subcutaneous biologics (in terms of revenues generated), featuring details on mechanism of action, development history, annual sales, technology platform (if available), and a comparison of their intravenous and subcutaneous formulations (if applicable).
An assessment of the various subcutaneous formulation technologies along with information on developers, type of pharmacological molecule, route of administration, mechanisms of action and primary advantage(s).
An insightful three-dimensional comparison of the subcutaneous formulation technology developers, based on pipeline strength, supplier power of the developer and primary advantages offered by their respective technologies.
Elaborate profiles of key technology developers, featuring a brief overview of the company, its technology portfolio, product portfolio, financial information (if available), recent developments and an informed future outlook.
An analysis of collaborations and partnership agreements inked by the subcutaneous formulation technology developers since 2011
An in-depth review of the most advanced and popular subcutaneous drug delivery systems, including large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants
A comprehensive product competitiveness analysis of subcutaneous large volume wearable injectors, subcutaneous autoinjectors, subcutaneous needle-free injectors and pre-filled syringes
A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry's evolution, under a comprehensive SWOT framework
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below):
Phase of development
Approved
Pre-registration & Phase III
Phase II & Phase II/III
Type of molecule
Cell and gene therapies
Monoclonal antibodies
Proteins
Peptides (recombinant)
Vaccines
Others
Target therapeutic area
Autoimmune disorders
Blood disorders
Bone disorders
Genetic disorders
Metabolic disorders
Neurological disorders
Oncological disorders
Respiratory disorders
Others
Type of drug delivery system
Large volume wearable injectors
Autoinjectors
Prefilled syringes
Needle-free injectors
Drug reconstitution systems
Revenues from licensing deals
Upfront payments
Milestone payments
Key geographical regions
North America
Europe
Asia Pacific
Rest of the World
Transcripts of interviews held with the following senior level representatives of stakeholder companies
Deborah Bitterfield (Founder and Chief Executive Officer, Lindy Biosciences)
Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies)
Steve Prestrelski (Founder and Chief Scientific Officer, Xeris Pharmaceuticals), Hong Qi (Vice President, Product Development, Xeris Pharmaceuticals) and Scott Coleman (Senior Scientist, Formulation, Xeris Pharmaceuticals)
David Daily (Co-Founder and Chief Executive Officer, DALI Medical Devices)
Michael Reilly (Co-Founder and Chief Executive Officer and Co-Founder, Excelse Bio)
Poonam R Velagaleti (Co-Founder, i-novion)
Michael Hooven (Chief Executive Officer, Enable Injections)
Frederic Ors (Chief Executive Officer, Immunovaccine Technologies)
Patrick Anquetil (Chief Executive Officer, Portal Instruments)
Menachem Zucker (Vice President and Chief Scientist, Elcam Medical)
Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services) and Graham Reynolds (Vice President and General Manager, Global Biologics, West Pharmaceutical Services)
David Heuzé (Communication Leader, MedinCell)
Key companies covered in the report
Adocia
Ajinomoto Bio-Pharma Services
Arecor
Alteogen
Ascendis Pharma
Avadel Pharmaceuticals
Camurus
Creative BioMart
Creative Biolabs
DURECT
Eagle Pharmaceuticals
Halozyme Therapeutics
MedinCell
Xeris Pharmaceuticals
Serina Therapeutics
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html
Other Recent Offerings
1. Global Autoinjectors Market (3rd Edition), 2020-2030
2. Prefilled Syringes Market (5th Edition), 2020-2030
3. Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030
4. Large Volume Wearable Injectors Market (4th Edition), 2018-2030
Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com
Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
sales@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180 billion by 2030, predicts Roots Analysis here
News-ID: 2256742 • Views: …
More Releases from Roots Analysis
Dental 3D Printing Market to Reach $15.8 Billion by 2035, Growing at 13.5% CAGR …
The global dental 3D printing market, valued at USD 4.1 billion in 2025, will grow to USD 5.0 billion in 2026 and reach USD 15.8 billion by 2035, advancing at a CAGR of 13.5% across the forecast period. This growth reflects accelerating adoption of additive manufacturing across dental laboratories, prosthodontic clinics, and orthodontic practices worldwide, driven by a chronic and worsening global burden of oral disease. For investors, technology developers,…
Deep Learning in Drug Discovery and Diagnostics Market to Reach $34.5 Billion by …
The global deep learning in drug discovery and diagnostics market, valued at USD 6.4 billion in 2025, will grow to USD 8.2 billion in 2026 and reach USD 34.5 billion by 2035, advancing at a compound annual growth rate of 17.3% over the forecast period. This expansion reflects accelerating adoption of neural network-based technologies across pharmaceutical R&D and clinical diagnostics, as more than 200 companies compete to bring AI-native solutions…
3D Cell Culture Market to Reach USD 8.90 Billion by 2035, Growing at 14.6% CAGR …
The global 3D cell culture market, valued at USD 2.16 billion in 2025 and projected to reach USD 2.61 billion in 2026, will grow to USD 8.90 billion by 2035, compounding at 14.6% annually over the forecast period. This growth reflects a fundamental shift in biomedical research methodology, as pharmaceutical companies, academic institutions, and contract research organizations accelerate their adoption of three-dimensional cell models to replace conventional animal testing and…
3D Bioprinting Market to Reach $23.1 Billion by 2035 at 17.7% CAGR | Stratasys, …
The global 3D bioprinting market, valued at USD 4.0 billion in 2024, is on course to reach USD 4.6 billion in 2025 and USD 23.1 billion by 2035, expanding at a compound annual growth rate (CAGR) of 17.7% over the forecast period. This sharp growth trajectory reflects intensifying demand across regenerative medicine, tissue engineering, and pharmaceutical drug development, as clinical researchers and biopharmaceutical companies accelerate adoption of bioprinting platforms capable…
More Releases for Pharma
Schizophrenia Market: Expanding Revenue Landscape to 2034 - DelveInsight | Teva …
The Key Schizophrenia Companies in the market inlclude - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva Pharmaceuticals, and others.
DelveInsight's report "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2034" provides a comprehensive analysis of the Schizophrenia landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As…
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the…
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis.
Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382
The Indomethacin Global Market Research Report provides close monitoring…
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.
Global Roxatidine Market overview:
Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the…
